Partenariat

Articles

• Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
  28 January 2019, by Jonathan NOWAK

  The partnership will develop new molecules for the treatment of brain diseases
  Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
  This agreement is part of Vect-Horus’ strategy to leverage (…)

• Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
  28 January 2019, by Jonathan NOWAK

  Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

• Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
  This project received support (label) from the EUROBIOMED Biocluster.

• Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
  28 January 2019, by Jonathan NOWAK

  The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

• Vect-Horus announces agreement with Johnson&Johnson Innovation
  18 January 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• Relocation of the company to support its development
  1 October 2019, by Elodie DORMES

  Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.